Net product sales by product type were as follows (in millions): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | COVID(1) | | $ | 91 | | | $ | 114 | | | $ | 436 | | | $ | 198 | | RSV | | 3 | | | — | | | 10 | | | 2 | | | | | | | | | | | | Total | | $ | 94 | | | $ | 114 | | | $ | 446 | | | $ | 200 | |
_______ (1)Includes sales of Spikevax and mNEXSPIKE. The following table summarizes product sales provision adjustments for the periods presented (in millions): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | Gross product sales | | $ | 122 | | | $ | 176 | | | $ | 472 | | | $ | 281 | | Product sales provision: | | | | | | | | | Wholesaler chargebacks, discounts and fees | | (50) | | | (62) | | | (39) | | | (84) | | Returns, rebates and other fees | | 22 | | | — | | | 13 | | | 3 | | Total product sales provision adjustments | | $ | (28) | | | $ | (62) | | | $ | (26) | | | $ | (81) | | | Net product sales | | $ | 94 | | | $ | 114 | | | $ | 446 | | | $ | 200 | |
The following table summarizes other revenue for the periods presented (in millions): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Stand-ready manufacturing revenue | | $ | 31 | | | $ | 17 | | | $ | 63 | | | $ | 29 | | Collaboration revenue (Note 5) | | 15 | | | 4 | | | 20 | | | 5 | | | Grant revenue | | 2 | | | 5 | | | 2 | | | 6 | | Licensing and royalty revenue | | 3 | | | 2 | | | 3 | | | 10 | | | Total other revenue | | $ | 51 | | | $ | 28 | | | $ | 88 | | | $ | 50 | |
|